Recruiting

Ultrasound Guided Microwave Ablation

Sponsor:

Banner Health

Code:

NCT07817147

Conditions

Pancreatic Cancer

Liver Cancer (Locally Advanced or Metastatic)

Pancreatic Cancer Non-resectable

Pancreatic Cancer Stage III

Pancreatic Cancer Stage IV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EUS-Guided MWA Device

Study Details

Brief summary:

The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.

Conditions

Pancreatic Cancer

Liver Cancer (Locally Advanced or Metastatic)

Pancreatic Cancer Non-resectable

Pancreatic Cancer Stage III

Pancreatic Cancer Stage IV

Study ID

NCT07817147

Start date

Feb 19, 2026

Status verified date

Sep, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Feb, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female ≥18 years of age
  • Willing and able to provide written informed consent
  • Histologically confirmed locally advanced, unresectable or metastatic cancer (Stage III or IV)
  • At least 1 tumor that is indicated for MWA, and the location of target tumor must be accessible via EUS through the gastric wall (eg, pancreas, liver, etc).
  • The tumor(s) must be ≥1 cm in diameter

Exclusion Criteria:

  • Participant is a candidate for upfront resection of pancreatic cancer
  • Participation in another clinical trial that involves local ablation or any other local therapy that could affect the target organ or lesions treated in this study
  • Any condition that, in the opinion of the investigator, may increase the risk to the participant's safety or well-being

Study Design

Enrollment

75 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Endoscopic Ultrasound (EUS) - Guided Microwave Ablation (MWA) Device Group

This is a open label feasibility study and only eligible participants will be enrolled into the single arm of the study to receive MWA with this specific device.

Interventions

EUS-Guided MWA Device

The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.

Primary outcome measure

  • To assess the success of energy delivery during treatment with the device [ Time Frame: From first MWA procedure to the end of treatment at Week 5 or 9 ]

Central Contacts and Locations

Central contacts

Neil Sharma, MD

(480) 356 - 6444neil.sharma@bannerhealth.com

Locations

Banner MD Anderson Cancer Center and Gateway Hospital

Recruiting

Gilbert, Arizona, United States, 85234

Contacts

Neil Sharma, MD

480-256-6444neil.sharma@bannerhealth.com

More Information

Sponsor

Banner Health

Last update posted

Sep 14, 2026

Last verified

Sep, 2026

Keywords

  • Locally Advanced
  • Unresectable
  • Metastatic

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-15. This information was provided to ClinicalTrials.gov by Banner Health on 2026-09-14.